TY - JOUR
T1 - Evaluation of the accelerate pheno system for identification of acinetobacter clinical isolates and minocycline susceptibility testing
AU - Bowler, Sarah L.
AU - Towne, Justin W.
AU - Humphries, Romney M.
AU - Doi, Yohei
N1 - Funding Information:
This study was funded by Accelerate Diagnostics, Inc. The effort of Y.D. was supported by NIH grants R01AI104895, R21AI123747, and R21AI135522.
Funding Information:
This study was funded by Accelerate Diagnostics, Inc. The effort of Y.D. was supported by NIH grants R01AI104895, R21AI123747, and R21AI135522. J.W.T. and R.M.H. are employees of Accelerate Diagnostics, Inc. Y.D. has consulted for Roche, Tetraphase, Geom, and Recida and received speaking fees from Merck and Astellas.
Publisher Copyright:
© 2019 American Society for Microbiology. All Rights Reserved.
PY - 2019/3
Y1 - 2019/3
N2 - The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. Acinetobacter baumannii is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of A. baumannii identification and minocycline susceptibility testing by AXDX using 101 contemporary Acinetobacter sp. clinical isolates. Overall, the sensitivity for A. baumannii and A. baumannii complex identification was 100% (73/73) and 97.6% (82/84), respectively. Specificity for A. baumannii complex identification was 86.6% (13/15). The essential agreement of minocycline susceptibility results (1 log 2 MIC agreement) of AXDX MICs with reference broth microdilution was 98.0% (96/98). There were no very major errors or major errors. Overall, 24.5% (24/98) of results yielded minor errors. AXDX reliably identified A. baumannii and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.
AB - The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. Acinetobacter baumannii is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of A. baumannii identification and minocycline susceptibility testing by AXDX using 101 contemporary Acinetobacter sp. clinical isolates. Overall, the sensitivity for A. baumannii and A. baumannii complex identification was 100% (73/73) and 97.6% (82/84), respectively. Specificity for A. baumannii complex identification was 86.6% (13/15). The essential agreement of minocycline susceptibility results (1 log 2 MIC agreement) of AXDX MICs with reference broth microdilution was 98.0% (96/98). There were no very major errors or major errors. Overall, 24.5% (24/98) of results yielded minor errors. AXDX reliably identified A. baumannii and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.
UR - http://www.scopus.com/inward/record.url?scp=85062263889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062263889&partnerID=8YFLogxK
U2 - 10.1128/JCM.01711-18
DO - 10.1128/JCM.01711-18
M3 - Article
C2 - 30651391
AN - SCOPUS:85062263889
VL - 57
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
SN - 0095-1137
IS - 3
M1 - e01711-18
ER -